Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 37

January 24, 2024 00:41:31
Episode Cover

Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche

"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...

Listen

Episode 8

August 18, 2021 00:41:04
Episode Cover

Episode 8: David Rose, Rare Disease Speaker and Advocate

On today's podcast, speaker and rare disease advocate David Rose talks with Biorasi's Dr. Raul Silveira about occipital horn syndrome and supporting rare disease...

Listen

Episode 3

June 09, 2021 00:39:48
Episode Cover

Episode 3: Danielle Drayton, PhD, CEO of REACH Market Research

On today’s podcast, host Wayne Bowden, Vice President of Partnerships and Strategy at Biorasi, will be discussing insights into market research solutions for rare...

Listen